Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 7/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 7/20 | 0.41 |
| ▸ | KYNU | Q16719 | 2/20 | 0.40 |
| ▸ | NSD2 | O96028 | 4/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.37 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.37 |
| ▸ | LDHA | P00338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28046230 | 0.84 | TTR (0.45) | TTRSLC1A3SLC1A2SLC1A1KYNU | |
| SCHEMBL8584521 | 0.82 | NSD2 (0.40) | TTRSLC1A3SLC1A2SLC1A1NSD2 | |
| SCHEMBL21955661 | 0.79 | KYNU (0.36) | TTRSLC1A3SLC1A2SLC1A1KYNU | |
| SCHEMBL214991 | 0.78 | CA2 (0.57) | NSD2 | |
| SCHEMBL10964110 | 0.77 | KYNU (0.49) | TTRSLC1A3SLC1A2SLC1A1KYNU | |
| SCHEMBL10964802 | 0.77 | KYNU (0.49) | TTRSLC1A3SLC1A2SLC1A1KYNU | |
| SCHEMBL10765755 | 0.77 | TTR (0.41) | TTRKYNUNSD2HDAC3IDO1 | |
| SCHEMBL28639928 | 0.77 | CA12 (0.41) | TTRKYNUNSD2HDAC3IDO1 | |
| SCHEMBL10965364 | 0.76 | KYNU (0.48) | TTRSLC1A3SLC1A2SLC1A1KYNU | |
| SCHEMBL10966276 | 0.76 | KYNU (0.48) | TTRSLC1A3SLC1A2SLC1A1KYNU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11845807-B2 | Method and carrier complexes for delivering molecules to cells | CORNELL RESEARCH FOUNDATION, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230293624-A1 | METHODS FOR PREVENTING OR TREATING MITOCHONDRIAL PERMEABILITY TRANSITION | CORNELL RESEARCH FOUNDATION, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230149501-A1 | METHODS FOR REDUCING OXIDATIVE DAMAGE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-11180574-B2 | Method and carrier complexes for delivering molecules to cells | CORNELL RESEARCH FOUNDATION INC. (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3842055-A1 | USES OF AROMATIC-CATIONIC PEPTIDE | Cornell Research Foundation, Inc. (US) | 2021-06-30 | — | — | EP | disclosed |
| US-20210015887-A1 | METHODS FOR REDUCING OXIDATIVE DAMAGE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2021-01-21 | — | — | US | disclosed |
| US-20200299415-A1 | METHOD AND CARRIER COMPLEXES FOR DELIVERING MOLECULES TO CELLS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| EP-3381515-B1 | CARRIER COMPLEXES FOR DELIVERING MOLECULES TO CELLS | CORNELL RES FOUNDATION INC (US) | 2020-07-08 | — | — | EP | disclosed |
| EP-3659618-A1 | USES OF AROMATIC-CATIONIC PEPTIDE | Cornell Research Foundation, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| US-10584182-B2 | Method and carrier complexes for delivering molecules to cells | CORNELL RESEARCH FOUNDATION, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-20100204448-A1 | METHOD AND CARRIER COMPLEXES FOR DELIVERING MOLECULES TO CELLS | CORNELL RESEARCH FOUNDATION, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100190718-A1 | METHODS FOR PREVENTING OR TREATING MITOCHONDRIAL PERMEABILITY TRANSITION | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2010-07-29 | — | — | US | disclosed |
| US-7718620-B2 | Methods for preventing or treating ischemia-reperfusion injury of the kidney | CORNELL RESEARCH FOUNDATION, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7704954-B2 | Small peptides that are energy-independent, non-endocytotic; nontoxic, peptidase resistant | CORNELL RESEARCH FOUNDATION, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7576061-B2 | Methods for preventing mitochondrial permeability transition | CORNELL RESEARCH FOUNDATION, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7550439-B2 | administering aromatic cationic peptide for specifically target mitochondria; ischemia is due to stroke, sepsis, inflammatory process, arthritis, diabetes, liver disorders, viral infection, to a removed organ | CORNELL RESEARCH FOUNDATION, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20070027087-A1 | METHODS FOR PREVENTING MITOCHONDRIAL PERMEABILITY TRANSITION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-01 | — | — | US | disclosed |
| US-20060084606-A1 | administering aromatic cationic peptide for specifically target mitochondria; ischemia is due to stroke, sepsis, inflammatory process, arthritis, diabetes, liver disorders, viral infection, to a removed organ | CORNELL RESEARCH FOUNDATION, INC. | 2006-04-20 | — | — | US | disclosed |
| US-20050158373-A1 | Small peptides that are energy-independent, non-endocytotic; nontoxic, peptidase resistant | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-07-21 | — | — | US | disclosed |
| US-20040248808-A1 | Methods for preventing mitochondrial permeability transition | PUBLIC HEALTH SERVICE/NATIONAL INSTITUTES OF HEALTH (NIH) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204448-A1 | METHOD AND CARRIER COMPLEXES FOR DELIVERING MOLECULES TO CELLS | IAPP, CD47, ANXA6 | TTR 294/4885SLC1A3 622/4885SLC1A2 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.